Loading data for IGC — first visit, this takes a few seconds.

アラート

IGC Pharma Inc. (IGC)

NYSE American: IGC · リアルタイム株価 · USD

0.29

+0.01 (3.57%)

終値時点： Aug 12, 2026, 8:00 PM

3.57% (1D)

データがありません

買気配	0.28
時価総額	29.84M
売上高（TTM）	1.11M
純利益（TTM）	-6.45M
ベータ	0.46
EPS（TTM）	-0.06
PER（TTM）	n/a
予想PER	-3.36
PBR（TTM）	4.61
PSR（TTM）	26.98
Earnings Date	n/a

売気配	0.28
出来高	1,623,338
平均出来高（20日）	587,303
始値	0.28
前日終値	0.28
当日レンジ	0.28 - 0.29
52週レンジ	0.24 - 0.50
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

IGCについて

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheim...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 May 24, 2006

従業員数 70

上場取引所 NYSE American

ティッカー IGC

ウェブサイト https://igcpharma.com

企業情報の全文

業績

2025年のIGC Pharmaの売上高は1.27Mで、前年の1.34Mから-5.5%の減少でした。利益は-7.12Mで、-45.22%の減少でした。

財務諸表

決算サプライズ

IGC PharmaはMay 15, 2026に四半期決算を発表しました：

売上高は $317K で、予想を下回りました $0, うち -3.94% の前年比減少.

EPSは -0.02 で、予想を下回りました 0.00, うち 0.00% の前年比増加にあたります.

ニュース

4か月前 · TipRanks

IGC Pharma, New to The Street launch 12-part national media partnership

New to The Street announced a strategic 12-part media partnership with IGC Pharma (IGC). The multi-faceted campaign is designed to elevate IGC Pharma’s visibility across institutional and retail inves...

5か月前 · Zacks

electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates

electroCore (ECOR) delivered earnings and revenue surprises of +1.45% and -0.18%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

5か月前 · Zacks

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for ...

5か月前 · Zacks

Merck KGaA (MKKGY) Lags Q4 Earnings Estimates

Merck KGaA (MKKGY) delivered earnings and revenue surprises of -40.43% and +0.69%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

5か月前 · TipRanks

IGC Pharma expands Phase 2 CALMA trial with new clinical site

IGC Pharma (IGC) announced the addition of Visionary Investigators Network as a clinical research site participating in the Company’s Phase 2 CALMA trial evaluating IGC-AD1 for the treatment of agitat...

2ページ中1ページ

IGC Pharma Inc. (IGC)